UroGen Pharma (URGN) Expected to Announce Quarterly Earnings on Monday

by · The Cerbat Gem

UroGen Pharma (NASDAQ:URGN – Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect UroGen Pharma to post earnings of ($0.83) per share and revenue of $22.71 million for the quarter.

UroGen Pharma (NASDAQ:URGN – Get Free Report) last announced its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $11.51 on Monday. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma has a fifty-two week low of $8.94 and a fifty-two week high of $20.70. The company has a 50 day simple moving average of $10.54 and a two-hundred day simple moving average of $11.04. The company has a market capitalization of $530.69 million, a PE ratio of -3.65 and a beta of 0.66.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, April 28th. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target for the company. Guggenheim reissued a “buy” rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of UroGen Pharma in a research note on Monday, April 28th. Finally, Scotiabank initiated coverage on UroGen Pharma in a research note on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $32.86.

Check Out Our Latest Report on URGN

UroGen Pharma Company Profile

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Further Reading